Divisadero Street Capital Management Reduces Stake in Eton Pharmaceuticals

The investment firm lowered its position in the specialty pharmaceutical company by over 40% in the third quarter.

Mar. 16, 2026 at 9:34am

Got story updates? Submit your updates here. ›

Divisadero Street Capital Management LP has reduced its holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) by 40.1% during the third quarter, according to a regulatory filing. The firm now owns 298,000 shares of the company's stock, down from 497,716 shares previously.

Why it matters

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing generic and branded drugs for rare and underserved diseases. The reduction in Divisadero Street Capital's stake could signal a shift in investor sentiment around the company's prospects.

The details

Divisadero Street Capital Management lowered its position in Eton Pharmaceuticals by selling 199,716 shares during the third quarter. The firm's remaining holdings in Eton are now valued at $6.48 million. Other major investors in Eton include Geode Capital Management, Soleus Capital Management, and Millennium Management.

  • Divisadero Street Capital Management reported its reduced stake in Eton Pharmaceuticals in a regulatory filing on March 16, 2026.
  • The firm sold 199,716 shares of Eton during the third quarter of the previous year.

The players

Divisadero Street Capital Management LP

An investment management firm that has reduced its position in Eton Pharmaceuticals by over 40%.

Eton Pharmaceuticals, Inc.

A specialty pharmaceutical company focused on developing and commercializing generic and branded drugs for rare and underserved diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Divisadero Street Capital's stake in Eton Pharmaceuticals could signal a shift in investor sentiment around the company's prospects, though the reasons behind the firm's decision are not entirely clear from the available information.